Acute coronary syndrome
356 results
201 - 300
CCTA reduces need for hospitalization in low to moderate risk patients in ED
Antithrombotic agents in primary health care - For atrial fibrillation with ACS or PCI, apixaban plus clopidogrel (without aspirin) is preferred (AUGUSTUS)
- Concomitant use of clopidogrel and a PPI may increase risk of adverse CHD outcomes
- Excess enoxaparin increases adverse outcomes in non-ST elevation ACS
- Treatment of a near-drowning person
- ACS risk similar with normal ECG performed during presence or absence of chest pain
- Better medication adherence with intervention; clinical outcomes unchanged
- Low HS-troponin I accurate in identifying patients at low risk of cardiac events
- Adding ezetimibe to moderate-dose statin reduces nonfatal MI only (NNT = 58 for 6 years)
- Small study finds recurrent spontaneous coronary artery dissection risk not associated with subsequent pregnancy
- Platelet-function testing doesn't improve outcomes in elderly patients with stents after ACS
- Cholesterol lowering cost-effective in high-risk elderly
- Intensive lipid lowering reduces mortality following ACS
- Two-hour protocol identifies patients at low risk of ACS
- Restrictive transfusion strategy is best for hospitalized patients
- High-sensitivity troponin I of less than 5 ng/L has negative predictive value of 99.9% for cardiac death at 1 year
- Clinical decision rules for evaluating adults with chest pain in primary care are limited in number and utility — stay tuned
- In ACS, 5 yrs of invasive tx decreases MI but not all cause mortality (FRISC-II)
- Fewer major cardiac events with routine percutaneous coronary intervention in patients undergoing transcatheter aortic-valve implantation (NOTION-3)
- Routine stress testing after negative biomarker testing seldom helpful
- Invasive strategy best only for men and high-risk women with unstable angina/non-ST elevation MI
- Low-dose rivaroxaban improves outcomes in patients with ACS (ATLAS)
Intravenous immunoglobulin for the treatment of Kawasaki disease- Accelerated protocol identifies chest pain patients at low risk for major cardiac events
- Early treatment with ACE inhibitors in acute myocardial infarction
- Echocardiography as an outpatient procedure
- Intensive BP control modestly decreased the likelihood of a broad composite of CV events, but with methodologic limitations
- Percutaneous coronary intervention does not improve outcomes for patients with ischemic heart disease and LVEF of less than 35%
- For atrial fibrillation with stable coronary artery disease, edoxaban alone prevents more bad outcomes than edoxaban plus an antiplatelet agent
- Exercise stress test
- Nitrates for acute heart failure syndromes
- Clopidogrel plus aspirin vs aspirin alone for preventing cardiovascular events
- Similar outcomes after PCI in hospitals with or without on-site cardiac surgery (CPORT-E)
- Drug treatment for hypertension
- Overuse alert: treat-to-target LDL strategy of statin dosing is noninferior to high-intensity dosing
- Coronary sinus-reducing device improves symptoms for patients with refractory angina
- Clopidogrel monotherapy more effective than aspirin to prevent coronary events after PCI with drug-eluting stents (HOST-EXAM)
- Early invasive strategy does not reduce mortality for moderate to severe ischemic heart disease after 5.8 years (ISCHEMIA-EXTEND)
- In low-risk patients with ACS, noninvasive testing adds little to clinical evaluation
- Ticagrelor (Brilinta) is no better than aspirin—and may be worse—for adults after CABG
- Adults with nonobstructive vulnerable coronary plaques have fewer major cardiac events with PCI than with optimal medical therapy
- B vitamins, fish oil do not prevent CV events
- Omega‐3 fatty acids for the primary and secondary prevention of cardiovascular disease
- Adding CCTA to chest pain assessment reduces likelihood of nonfatal MI (SCOT-HEART)
- Prophylactic lidocaine for myocardial infarction
- Traditional approach to pretest probability of heart disease overestimates risk
- Dyspnoea
- Pioglitazone does not increase cardiovascular events (PROactive)
- Flu vaccine reduces risk of adverse CV events in high-risk patients
- Long-term outcomes better with CABG than PCI in pts with complex CAD (SYNTAX)
- Faster discharge but more downstream testing with use of CCTA in ED
- High-sensitivity troponin safely reduces admissions and duration of stay in the emergency department
- Corticosteroids for the treatment of Kawasaki disease in children
- Little if any benefit to early invasive strategy for stable angina and at least moderate reversible ischemia (ISCHEMIA trial)
- Systemic lupus erythematosus (SLE)
- Niacin not effective in CAD with low HDL cholesterol (AIM-HIGH)
- Less is more when it comes to blood transfusions
- In patients with vascular disease, treating sleep apnea does not reduce the risk of cardiovascular events
- Lipid lowering is beneficial for secondary prevention but not primary prevention in patients 75 years and older
- Similar number of cardiovascular events and reduced bleeding with abbreviated dual antiplatelet therapy after PCI
- Antiplatelet therapy for prevention of death, myocardial infarction, and stroke
- 6-month clopidogrel better than 24 after stent placement (PRODIGY)
- Clarithromycin associated with cardiovascular events
- Interpretation of adult ECG
- COVID-19 and other coronavirus infections
- Dialysate temperature reduction for intradialytic hypotension for people with chronic kidney disease requiring haemodialysis
- Mortality rate in patients with recent ACS and endoscopy is similar to that in patients with ACS and no endoscopy
- Tumours of haematopoietic and lymphoid tissues: general information
- Increased readmissions and adverse events with intensification of antihypertensive regimen on hospital discharge
- Taking furosemide on day of surgery does not increase intraop hypotension
- No reduction in postdischarge medication errors after pharmacist-led intervention
- Adenosine-diphosphate (ADP) receptor antagonists for the prevention of cardiovascular disease in type 2 diabetes mellitus: Cochrane systematic review
- Antiplatelet agents for chronic kidney disease
- Clopidogrel + ASA no better than ASA alone for high-risk patients
- Glycoprotein IIb-IIIa inhibitors for acute ischaemic stroke: Cochrane systematic review
- Hyperbaric oxygen therapy (HBOT)
- Small reduction in CV outcome after ischemic stroke with lower LDL target, but also harms; no change in all-cause mortality
- Interpreting BNP in patients with a history of HF
- Promoting patient utilisation of cardiac rehabilitation
- Statin therapy decreases cardiac events